Edwards Lifesciences beats Wall Street's forecast for the 4th quarter, but says its replacement mitral valve program was delayed while it waited for FDA approval to begin a 1st-in-human trial.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1fXHdvF
Cap comentari:
Publica un comentari a l'entrada